Overview

Event Highlights

Advancing earlier diagnosis and multidisciplinary treatment strategies for pancreatic cancer.
Integrating precision oncology, biomarker testing, and personalized therapies into clinical practice.
Connecting global experts to improve outcomes and shape the future of pancreatic cancer care.

Event Series

How I Treat

Date / Time

Nov 24, 2026

Save to

Google Calendar Outlook Calendar

How I Treat Pancreatic Cancer in 2026 is a global virtual medical congress dedicated entirely to pancreatic cancer, focusing on early diagnosis, multidisciplinary treatment strategies, precision oncology, and future directions in disease management.

The OncoDaily How I Treat series returns with a dedicated global summit on pancreatic cancer treatment, bringing together leading international experts to discuss the latest advances in pancreatic oncology in 2026.

Pancreatic cancer remains one of the most challenging diseases in oncology and is among the leading causes of cancer-related mortality worldwide. According to the World Health Organization, global cancer incidence continues to rise, highlighting the urgent need for earlier detection and more effective therapies. In 2022 alone, approximately 510,922 new pancreatic cancer cases and 467,409 deaths were reported worldwide. In the United States, an estimated 67,530 new cases and 52,740 deaths are expected in 2026.

Outcomes remain highly dependent on stage at diagnosis. While early-stage disease may occasionally be treated with curative-intent surgery, most patients continue to present with advanced or metastatic disease, where long-term survival remains limited. Nevertheless, recent years have brought meaningful progress.

The treatment landscape is evolving rapidly with the integration of multi-agent chemotherapy regimens, targeted therapies for actionable mutations, and biomarker-driven precision medicine. These innovations are reshaping the management of both pancreatic ductal adenocarcinoma and neuroendocrine tumors, improving survival and quality of life for selected patients.

About the Congress

How I Treat Pancreatic Cancer in 2026 is a global virtual medical congress dedicated to advancing the diagnosis and treatment of pancreatic cancer. The congress will focus on early detection, multidisciplinary care, surgical and systemic treatment strategies, precision oncology, and future directions in disease management.

Through expert-led presentations, case-based discussions, and international perspectives, the program will explore practical approaches to managing pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, and other pancreatic malignancies across different stages of disease.

Key topics will include diagnostic pathways, resectability assessment, neoadjuvant and adjuvant therapy, surgical management, treatment of locally advanced and metastatic disease, biomarker testing, targeted therapies, supportive and palliative care, clinical trials, and emerging treatment strategies.

By bringing together leading specialists from different countries and healthcare systems, the congress aims to encourage multidisciplinary collaboration, share real-world experience, and support the development of more effective and personalized approaches to pancreatic cancer care worldwide.

Who Should Attend?

This congress is designed for medical oncologists, surgical oncologists, gastrointestinal oncologists, pancreatic surgeons, gastroenterologists, radiation oncologists, radiologists, pathologists, nuclear medicine specialists, oncology nurses, oncology pharmacists, genetic counselors, palliative care professionals, researchers, patient advocates, and all healthcare professionals involved in the diagnosis, treatment, and supportive care of patients with pancreatic cancer.

Why To Attend?

How I Treat Pancreatic Cancer in 2026 will provide a global platform for leading experts and multidisciplinary cancer care professionals to discuss the latest developments in pancreatic cancer diagnosis, treatment, and research.

Participants will gain practical insights into multidisciplinary decision-making, learn from real-world clinical experiences, explore biomarker-driven and personalized treatment strategies, and join an international conversation focused on improving survival, quality of life, and outcomes for patients with pancreatic cancer.

How I Treat Pancreatic Cancer 2026 – Global Virtual Summit organized in partnership with Let’s Win Pancreatic Cancer

Speakers

Images	Name
	Markus Büchler- Germany Prof. Markus W. Büchler is an internationally renowned German surgeon and leading expert in pancreatic surgery and surgical oncology. He served as Professor and Chairman of the Department of General, Visceral and Transplant Surgery at Heidelberg University Hospital, Germany, for over two decades. Currently, he is Director of the Botton-Champalimaud Pancreatic Cancer Centre in Lisbon, Portugal. With an outstanding contribution to pancreatic cancer research, clinical practice, and surgical innovation, Professor Büchler is recognized as one of the world's leading authorities in pancreatic surgery.
	Philip A. Philip- USA Prof. Philip A. Philip, MD, PhD, FRCP, is an internationally renowned medical oncologist and a leading expert in pancreatic and gastrointestinal cancers. He is Director of Gastrointestinal Oncology and Co-Director of the Pancreatic Cancer Center at the Henry Ford Cancer Institute in Detroit, USA. He also serves as Professor of Oncology and Pharmacology at Wayne State University School of Medicine. With extensive contributions to pancreatic cancer research, clinical trials, and the development of innovative cancer therapies, Professor Philip is recognized as a prominent international leader in gastrointestinal oncology.
	Talia Golan- Israel Prof. Talia Golan, MD, is an internationally recognized Israeli medical oncologist, clinician-scientist, and leading expert in pancreatic cancer. She is Head of the Sheba Pancreatic Cancer Center and Associate Professor at the Faculty of Medicine, Tel Aviv University, Israel. Her clinical and research work focuses on pancreatic cancer, particularly hereditary BRCA1/2-associated pancreatic cancer, precision medicine, and the development of innovative targeted therapies. Professor Golan has made significant contributions to translational research and international clinical trials, including the landmark POLO study, advancing personalized treatment approaches for pancreatic cancer.
	Shiraj Sen- USA Dr. Shiraj Sen, MD, PhD, is an internationally recognized medical oncologist specializing in early-phase clinical trials and the development of innovative cancer therapies. He serves as Clinical Director of NEXT Oncology in Dallas, Texas, USA, where he focuses on advancing novel therapeutic approaches for patients with advanced cancers. His research interests include molecular profiling, targeted therapies, and precision oncology, with particular contributions to the development of new treatment strategies for pancreatic cancer. Dr. Sen is actively involved in clinical research and the evaluation of emerging anticancer agents.
	Tiago Felismino- Brazil Dr. Tiago Cordeiro Felismino, MD, MSc, is a Brazilian medical oncologist specializing in gastrointestinal cancers, with particular expertise in pancreatic, gastric, esophageal, and hepatobiliary malignancies. He is affiliated with the Clinical Oncology Department at A.C.Camargo Cancer Center in São Paulo, Brazil, where he serves as a leader in the Upper Gastrointestinal Cancer Reference Center. He completed his medical training at the Federal University of Ceará and specialized in clinical oncology at A.C.Camargo Cancer Center. He holds a Master's degree in Precision Cancer Medicine from the University of Oxford, UK. His clinical and research interests include precision oncology, immunotherapy, and innovative treatment strategies for gastrointestinal cancers.

News & Updates